Microbix Biosystems Inc.

276 articles with Microbix Biosystems Inc.

• Governments of Ontario and Canada Invest in Microbix

  3/20/2023

  Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces that it is undertaking further expansions to its capabilities and capacity for manufacturing specialized products relating to diagnostic testing for infectious diseases.

• Microbix Supporting Australian Point-of-Care Testing ProgramQAPs used in Diagnostic Testing for STIs in Remote Communities

  3/1/2023

  Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its Quality Assessment Products (“QAPs™”) are now supporting test accuracy within a program to provide Point-of-Care Testing (“PoCT”) for Sexually-Transmitted Infections (“STIs”) in remote communities across Australia.

• Microbix Announces Issuance of Stock Options - February 27, 2023

  2/27/2023

  Microbix Biosystems Inc. announces the issuance of stock options under its shareholder-approved 2018 stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.

• Microbix Reports Results for Q1 Fiscal 2023 Sales of $2.5 million, Net Loss of $1.3 million

  2/9/2023

  Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator, manufacturer, and exporter, reports results for its first quarter ended December 31, 2022 (“ Q1 ”), a period in which reduced sales across two major product lines resulted in the first quarterly net loss in two years.

• Microbix Presenting Results of Collaboration with Health PEIQAPs for HPV Test Verification within Cervical Cancer Screening Program

  2/6/2023

  Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting results of its collaboration with the Microbiology Laboratory of the Queen Elizabeth Hospital of Health PEI (“ Health PEI ”), in support of provincial adoption of molecular diagnostic (“ MDx ”) screening for Human Papillomavirus (“ HPV ”) infections.

• Microbix Launches QAP to Support “Monkeypox” Testing

  1/30/2023

  Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator, manufacturer, and exporter, announces that it is launching a new quality assessment product (“ QAP™ ”) to support molecular diagnostic (“ MDx ”) testing for the Non-Variola Orthopoxvirus (“ Mpox ”), the cause of the cutaneous infection colloquially-known as “Monkeypox.”

• Microbix Reports Record Sales for Fiscal 2022

  12/22/2022

  Microbix Biosystems Inc. reports results for its year and fourth quarter ended September 30, 2022, with record sales and continued positive net earnings, plus ongoing progress upon its strategic goal of increasing its capacity for medical devices production and, over time, to thereby grow sales, margins, and earnings.

• Microbix Presenting Test-Workflow Validation Results at EMMDMSwab® & PROCEEDx™FLOQ® Supporting Self-Collection for HPV Screening Programs

  10/6/2022

  Microbix Biosystems Inc. will present results of novel methods to support diagnostic accuracy and whole-process workflow validation of cervical cancer screening tests on self-collected patient specimens.

• Microbix Reports Results for Q3 Fiscal 2022Q3 Sales of $5.0 million, Q3 Net Earnings of $0.6 million

  8/11/2022

  Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and year-to-date fiscal 2022 ended June 30, 2022, with strong sales and continued positive net earnings, plus ongoing progress upon its strategic goal of increasing its capacity for medical devices production to thereby continue growing sales, margins, and earnings.

• Microbix Executes Substantial QAPs Supply AgreementMicrobix QAPs to Support Molecular & Antigen Test Platforms for Multiple Diseases

  8/10/2022

  Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator, manufacturer, and exporter, announces the execution of a purchase and supply agreement (“ Agreement ”) by which Microbix “ QAPs™ ” quality assessment products will support assays on industry-leading molecular (PCR) and antigen-based point-of-care testing platforms.

• Microbix Presenting STI Multiplex Test Controls at AACCQuality Control Materials for Genital Ulcer Disease Molecular Assays

  7/26/2022

  Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces it is presenting about the utility of its multi-pathogen (“ multiplex ”) and swab-formatted Quality Assessment Products (“ QAPs™ ”) to monitor molecular assays that detect and distinguish between four sexually-transmitted infections (each an “ STI ”) that cause Genital Ulcer Disease (“ GUD ”) – at the 2022 conference.

• Microbix Presenting Test Validation Methods at AACCUsage of QAPs to Validate Whole Workflow Quality Control of Testing

  6/3/2022

  Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces it is presenting about the utility of its Quality Assessment Products (“ QAPs™ ”) to monitor the end-to-end diagnostic process, including the impact of “preanalytical” sample-handling variables on test accuracy, at the 2022 “Preanalytical Phase Conference” of the American Association of Clinical Chemistry.

• Microbix Reports Record Results for Q2 Fiscal 2022Record Q2 Sales of $4.9 million, Q2 Net Earnings of $0.7 million

  5/12/2022

  Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2022 ended March 31, 2022,

• Microbix Presenting Omicron Test Control Results at CVSQAPs Supporting Molecular Diagnostic Tests for Dominant COVID-variant

  4/29/2022

  Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), announces it will present performance results of its Quality Assessment Products (“QAPs™”) supporting molecular-diagnostic tests for the Omicron variant of the SARS-CoV-2 virus (“Omicron”) at the 2022 Clinical Virology Symposium of the American Society for Microbiology (“CVS”) taking place in West Palm Beach, Florida from May 1-4, 2022.

• Microbix Presenting at the 2022 Bloom Burton ConferenceHealthcare Investor Conference in Toronto on May 2 & 3, 2022

  4/28/2022

  Microbix Biosystems Inc. announces it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference taking place at the Metro Toronto Convention Centre, North Building, in Toronto, Ontario, Canada on May 2nd and 3rd, 2022.

• Microbix Presenting Respiratory Virus Controls Data at Two Events

  4/19/2022

  Microbix Biosystems Inc. announces it will be presenting performance results of its quality assessment products that support molecular-diagnostic screening-tests for respiratory viruses at two industry congresses – “Labquality Days” in Helsinki, Finland April 20-21, 2022 and “ECCMID 2022” in Lisbon, Portugal, April 23-26, 2022.

• Microbix Presenting HPV Product Results at EUROGINQAPs Supporting Screening-Tests for High-Risk Human Papilloma Viruses

  4/8/2022

  Microbix Biosystems Inc. announces it will present performance results of its Quality Assessment Products (“ QAPs™ ”) supporting Human Papillomavirus (“ HPV ”) molecular-diagnostic screening-tests at the 2022 annual congress of the European Research Organization on Genital Infection and Neoplasia (“ EUROGIN ”) taking place in Düsseldorf, Germany from April 10=12, 2022.

• Microbix Invests to Further Scale Its Business

  3/29/2022

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces investment in programs to upgrade, digitize and fully-integrate its Quality Management System and its Enterprise Resource Planning platforms — to better enable its business growth trajectory.

• Microbix Announces Issuance of Stock Options - Feb 24, 2022

  2/24/2022

  Microbix Biosystems Inc. announces the issuance of stock options under its shareholder-approved 2018 stock option plan, as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.

• Microbix Announces Nomination to Board of DirectorsFor Appointment of Jennifer Stewart, Accomplished Business Leader

  2/22/2022

  Microbix Biosystems Inc. announces that Ms. Jennifer Stewart, an accomplished leader in Canadian business, government, and public affairs, has been nominated to become a member of its Board of Directors.